Close

cGMP CAR-T Lentivirus Production Service

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

cGMP lentivirus production for CAR-T therapies is a critical step in generating safe and effective viral vectors for gene modification. This process follows stringent guidelines to ensure that the viral vectors used for CAR-T therapies meet regulatory standards for quality, safety, and efficacy. Creative Biolabs provides high-quality, clinical-grade lentiviral vectors tailored to meet the needs of cutting-edge gene therapies.

CGMP Lentivirus

cGMP lentivirus is crucial in advanced medical applications, particularly for CAR-T therapy, gene therapy, and immunotherapy. In CAR-T therapy, lentiviral vectors are used to deliver chimeric antigen receptor (CAR) genes into T cells, enabling them to specifically target and destroy cancer cells. Lentivirus is also widely used in gene therapy to treat genetic disorders by delivering corrective genes to patient cells, ensuring safe and effective therapeutic outcomes. Additionally, lentiviral vectors are applied in stem cell modification, vaccine development, and immunotherapies to engineer cells that fight diseases such as cancer and viral infections. cGMP-compliant production guarantees that these vectors meet the rigorous safety, potency, and purity standards required for clinical and commercial use.

Our Service

Our cGMP Lentivirus Production service for CAR-T therapy provides high-quality, clinical-grade lentiviral vectors tailored to meet the needs of cutting-edge gene therapies. Adhering to stringent regulatory standards, we offer scalable production platforms, from research-grade to commercial-scale manufacturing, ensuring safety, efficacy, and regulatory compliance. With advanced vector design, producer cell line development, and purification processes, we guarantee superior vector yield and purity. Comprehensive quality control, including sterility testing and potency validation, ensures your vectors are ready for clinical trials or therapeutic use, backed by full regulatory support.

Fig.2 Advantages. (Creative Biolabs Original)

Process of CGMP Lentivirus Production

Our CGMP lentivirus production process for CAR-T involves several key steps to ensure quality and safety. First, producer cells (typically HEK293T) are developed and optimized for high-yield lentiviral vector production. Plasmids containing the CAR gene and necessary helper sequences are transfected into these cells. Once the virus is produced, it is harvested and purified using techniques like tangential flow filtration (TFF) and ultracentrifugation to remove impurities. Quality control testing ensures sterility, potency, and the absence of replication-competent lentivirus. Finally, the purified lentiviral vectors are cryopreserved, stored under stringent conditions, and fully documented to meet regulatory standards.

Fig.3 Process. (Creative Biolabs Original)

Benefits

  • Reliability and scalability: We offer scalable production from small research batches to large clinical-grade and commercial batches.
  • Regulatory compliance: Assurance that all lentiviral vectors meet the necessary safety, purity, and efficacy standards required.
  • Expertise: Leverage specialized knowledge in viral vector production, quality control, and regulatory compliance.

Contact Us

Looking to advance your CAR-T therapy development with our cGMP lentivirus production services? Contact us today to explore how we can meet your specific project needs and support both your research goals. Our dedicated team of experts is ready to provide answers to your questions and offer customized solutions that will help fast-track your progress from research to therapeutic application.

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.